In a comprehensive study of RASSF1A promoter methylation in breast tissue samples, it was demonstrated that primary tumors had significantly higher promoter methylation compared to healthy breast reduction samples, while normal breast samples at a distance of the tumor had intermediate methylation levels [24]. This evidence concerns the gene RASSF1 and neoplasm.